195 related articles for article (PubMed ID: 33460667)
1. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment.
Wang Z; Wang J; Hu J; Chen Y; Dong B; Wang Y
Life Sci; 2021 Jun; 274():119069. PubMed ID: 33460667
[TBL] [Abstract][Full Text] [Related]
2. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
[TBL] [Abstract][Full Text] [Related]
4. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
Wang MM; Lin S; Chen YM; Shu J; Lu HY; Zhang YJ; Xie RY; Zeng LY; Mu PW
Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
7. Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
Tao T; Wu P; Wang Y; Liu W
BMC Endocr Disord; 2018 Feb; 18(1):14. PubMed ID: 29482528
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
10. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
11. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
Kostev K; Schokker E; Jacob L
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
Du J; Liang L; Fang H; Xu F; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
Diabetes Obes Metab; 2017 Nov; 19(11):1513-1520. PubMed ID: 28296055
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Pan CY; Yang W; Tou C; Gause-Nilsson I; Zhao J
Diabetes Metab Res Rev; 2012 Mar; 28(3):268-75. PubMed ID: 22081481
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.
Men P; Li XT; Tang HL; Zhai SD
PLoS One; 2018; 13(5):e0197321. PubMed ID: 29787616
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
18. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
